ENVISTA HOLDINGS Reports Fourth Quarter Earnings Results for FY2022
March 7, 2023
Earnings Overview
ENVISTA HOLDINGS ($NYSE:NVST) announced its financial results for the fourth quarter of FY2022, which ended on December 31 2022, on February 8 2023. Total revenue for the period was USD 73.5 million, a decrease of 14.3% from the same quarter of the previous year. Net income, however, increased 1.4% to USD 660.8 million.
Transcripts Simplified
Envista Holdings reported fourth quarter sales of $660.8 million, an increase of 1.4% from the prior year. The quarter was negatively impacted by currency exchange rates, while acquisitions contributed 3.1% of growth. Core sales growth was 2.3%, compared to the fourth quarter of 2021. Core sales in their Specialty Products and Technology segment increased 4.5%, driven by very strong growth in Western Europe, offset by significant declines in China and Russia. Their Equipment and Consumables segment core sales decreased 0.9%, due to the continued slowdown in equipment volumes, offset by very strong growth in their consumables business.
Adjusted gross margin for the quarter was 56.2%, a decrease of 90 basis points, compared to the prior year. Adjusted EBITDA margin for the quarter was 20.9%, which is 240 basis points higher than Q4 of 2021. Adjusted EPS was $0.52 from continuing operations, compared to $0.46 in the comparable period of the prior year, representing a 13% increase year-over-year.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Envista Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 2.57k | 243.1 | 9.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Envista Holdings. More…
| Operations | Investing | Financing |
| 182.7 | -657.3 | 12.5 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Envista Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.59k | 2.38k | 25.78 |
Key Ratios Snapshot
Some of the financial key ratios for Envista Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -2.3% | 4.8% | 12.5% |
| FCF Margin | ROE | ROA |
| 4.2% | 4.9% | 3.1% |
Price History
The stock opened at $41.0 and closed at $40.7, representing a decline of 2.0% compared to the previous day’s closing price of $41.5. Overall, ENVISTA HOLDINGS’ fourth quarter report was a positive one, and the company is well-positioned to continue its growth trajectory in the coming year. Live Quote…
Analysis
At GoodWhale, we have conducted an analysis of ENVISTA HOLDINGS‘s fundamentals and have determined that it is a high risk investment in terms of financial and business aspects. Specifically, we have identified three risk warnings in income sheet, balance sheet, and cashflow statement. These areas of concern are key indicators of potential financial instability and less-than-ideal returns for investors. As such, we recommend that potential investors carefully evaluate the information available to them and make sure they are comfortable taking on the risk associated with investing in ENVISTA HOLDINGS. We have made all of our analysis available to registered users, so if you would like to take a deeper dive into our findings, please join us! We are confident that our data-driven approach can help you make an informed decision about whether ENVISTA HOLDINGS is right for your investment portfolio. More…
Peers
Its main competitors are Medikit Co Ltd, Nihon Kohden Corp, and Fukuda Denshi Co Ltd. Envista has a strong market presence in the US, Europe, and Asia Pacific.
– Medikit Co Ltd ($TSE:7749)
As of 2022, Medikit Co Ltd has a market cap of 41.17B and a Return on Equity of 6.14%. The company produces and sells medical equipment and supplies. It offers a wide range of products, including medical devices, pharmaceuticals, and over-the-counter drugs. Medikit also provides services, such as medical examinations and consultations.
– Nihon Kohden Corp ($TSE:6849)
Nihon Kohden is a Japanese manufacturer of medical equipment, with a particular focus on patient monitoring systems. The company has a market cap of 278.79B as of 2022 and a return on equity of 13.19%. Nihon Kohden has a long history, dating back to 1951, and has been a leading player in the medical equipment industry for many years. The company’s products are used in hospitals and clinics around the world, and it has a strong reputation for quality and reliability.
– Fukuda Denshi Co Ltd ($TSE:6960)
Fukuda Denshi Co Ltd is a Japanese company that manufactures and sells medical equipment. The company has a market cap of 138.83B as of 2022 and a Return on Equity of 9.95%. Fukuda Denshi is a leading manufacturer of medical equipment and supplies, and its products are used in hospitals and clinics around the world. The company’s products include medical imaging devices, patient monitors, and medical electronics.
Summary
ENVISTA HOLDINGS reported its financial results for the fourth quarter of FY2022 on February 8 2023, with total revenue of USD 73.5 million, representing a year-over-year decrease of 14.3%. Net income was USD 660.8 million, an increase of 1.4%. Analysts suggest that investors should take into consideration that these results demonstrate a decrease in revenue but an increase in net income, indicating a potential opportunity to invest in the company. Further analysis is needed to fully understand the financial health of ENVISTA HOLDINGS and make a more informed investing decision.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
